Johnson & Johnson Innovation Industry Excellence Awards recognise biotechnology leaders at AusBiotech 2014
30 October, 2014Medtech featured strongly when the prestigious Johnson & Johnson Innovation Industry Excellence Awards 2014 were announced, recognising those at the forefront of Australia's world-class biotech, medical technology and healthcare sectors in Australia.
GM crops: new directions
29 October, 2014 by Graeme O'NeillAustralia's GM crop revolution has stalled, after an auspicious debut in 1989 when South Australia became the first state in the world to release a genetically modified organism into the environment.
Federal government announces Expert Review of Medicines and Medical Devices Regulation
28 October, 2014Further to the recent launch of the Industry Innovation and Competitiveness Agenda, the federal government has announced the establishment of an independent panel to undertake a review of medicines and medical devices regulation in Australia.
Antisense paves way for IND for MS drug
28 October, 2014 by Dylan Bushell-EmblingAntisense Therapeutics (ASX:ANP) has received positive feedback from the US FDA on plans to conduct an IND-enabling phase IIb trial of MS drug candidate ATL1102.
AusBiotech 2014 kicks off on Wednesday
27 October, 2014The AusBiotech national conference will this week bring together the entire biotechnology 'ecosystem' to share ideas and progress their biotechnology development work.
Clinuvel's Scenesse gets EMA nod in EPP
27 October, 2014 by Dylan Bushell-EmblingThe European Medicines Agency has voted to grant marketing authorisation to Clinuvel's Scenesse in rare and severe skin disorder erythropoietic protoporphyria.
ResMed quarterly profit grows 3%
24 October, 2014 by Dylan Bushell-EmblingResMed (ASX:RMD) has reported its results for its fiscal first quarter and has unveiled new and improved patient management platforms for its sleep-disordered breathing treatment devices.
Commonwealth makes IP data available online
23 October, 2014In a world first, the Australian Government has announced it will make 100 years of intellectual property (IP) rights data available online in order to make finding collaboration partners easier and allow the mapping of innovation.
Auspherix gets $1m in financing
23 October, 2014 by Dylan Bushell-EmblingThe Medical Research Commercialisation Fund has granted $1m in financing to early-stage anti-infectives company Auspherix.
Anatara preps manufacturing for Detach trial
21 October, 2014 by Dylan Bushell-EmblingAnatara Lifesciences is taking steps towards registration with the AVPMA for non-antibiotic diarrhoea treatment Detach, initiating the manufacturing process for Australian trials in pigs.
ATSE elects 2014 Fellows
21 October, 2014The Australian Academy of Technological Sciences and Engineering (ATSE) has elected 25 new Fellows for 2014. The academy is an independent body of 800 eminent scientists and engineers seeking to enhance Australia's prosperity through technological innovation.
AusBiotech tells inquiry why 1.5% cut is not benign for biotech
21 October, 2014AusBiotech said in its submission to the Inquiry into the 'Tax and Superannuation Laws Amendment (2014 Measures No 5) Bill 2014' that the seemingly small but not benign change, announced in the May 2014 Federal Budget, will permanently impact companies in tax loss.
Randox aspirin-resistance test gets TGA tick
17 October, 2014 by Dylan Bushell-EmblingThe TGA has approved a Randox Laboratories test to help measure aspirin resistance in patients taking the drug to reduce heart attack risk.
Anatara Lifesciences trading on ASX
16 October, 2014 by Dylan Bushell-EmblingAnatara Lifesciences (ASX:ANR) has started trading on the ASX, after conducting a $7m IPO to raise funds to commercialise its non-antibiotic diarrhoea treatment.
AusBiotech welcomes industry agenda as a win for common sense
16 October, 2014Long-awaited restoration in the tax treatment of employee share schemes (ESS) and the announcement that Australian manufacturers of medical devices will be able to register routine medical devices using certification from European bodies were amid the changes that AusBiotech warmly welcomed when the government released its Industry Innovation and Competitiveness Agenda (IICA).
